AC Immune Signs With Janssen Pharmaceuticals for Alzheimer’s Disease Treatment Using Anti-Tau Vaccination

AC Immune Signs With Janssen Pharmaceuticals for Alzheimer’s Disease Treatment Using Anti-Tau Vaccination
AC Immune SA recently announced it has signed an exclusive worldwide license agreement and collaboration contract with Janssen Pharmaceuticals, Inc. to develop and commercialize anti-Tau vaccines to treat Alzheimer’s disease. According to the contract, Janssen Research & Development, an affiliate of Janssen Pharmaceuticals, Inc., will advance the development of the vaccine ACI-35 which is currently going through a Phase Ib clinical trial in patients

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *